$310 Million is the total value of MPM ASSET MANAGEMENT LLC's 12 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was 27.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PETX | Aratana Therapeutics Inc. | $83,105,000 | +16.9% | 4,351,048 | 0.0% | 26.84% | +33.9% | |
| PTLA | Portola Pharmaceuticals, Inc. | $62,865,000 | -3.7% | 2,441,344 | 0.0% | 20.30% | +10.3% | |
| EPZM | EpiZyme, Inc. | $59,914,000 | -48.0% | 2,880,485 | 0.0% | 19.35% | -40.4% | |
| MGNX | New | MacroGenics, Inc. | $48,852,000 | – | 1,780,955 | +100.0% | 15.78% | – |
| PIP | PharmAthene, Inc. | $11,807,000 | -11.4% | 6,347,614 | 0.0% | 3.81% | +1.4% | |
| VSTM | Verastem, Inc. | $11,780,000 | -8.4% | 1,033,324 | 0.0% | 3.80% | +4.9% | |
| KBIO | Kalobios Pharmaceuticals, Inc. | $11,638,000 | -2.2% | 2,632,928 | 0.0% | 3.76% | +12.0% | |
| CNAT | Conatus Pharmaceuticals, Inc. | $7,689,000 | -35.8% | 1,192,080 | 0.0% | 2.48% | -26.5% | |
| PCRX | Sell | Pacira Pharmaceuticals, Inc. | $5,749,000 | -85.5% | 100,000 | -87.9% | 1.86% | -83.4% |
| ETRM | EnteroMedics, Inc. | $3,406,000 | +63.2% | 1,669,753 | 0.0% | 1.10% | +87.1% | |
| AVEO | Sell | AVEO Pharmaceuticals, Inc. | $2,511,000 | -44.8% | 1,372,118 | -37.9% | 0.81% | -36.8% |
| SGMO | New | Sangamo biosciences, Inc. | $312,000 | – | 22,487 | +100.0% | 0.10% | – |
| ZLCS | Exit | Zalicus, Inc. | $0 | – | -5,566,980 | -100.0% | -1.88% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-01-23
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
| Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
| Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
| Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
| Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
| Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
| Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
| TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
| Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
| EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-09-07 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-05 |
| 4 | 2023-05-24 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.